Matt Abernethy, Chief Financial Officer at NEUROCRINE BIOSCIENCES INC (NBIX), sold 5,116 shares at $116.85 ($598K) on 2025-02-13, disclosed to the SEC on 2025-02-14.
Scheduled sale ($598k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $116.85 | 1,352 | $158K | 26.4% |
| 2 | $116.85 | 1,352 | $158K | 26.4% |
| 3 | $116.87 | 1,206 | $141K | 23.6% |
| 4 | $116.87 | 1,206 | $141K | 23.6% |
| Total | $116.86 avg | 5,116 | $598K | 100% |
| Filing → |
| NBIX | SELL | 2025-02-04 | $392K | — | Filing → |
| NBIX | SELL | 2024-08-15 | $2.1M | — | Filing → |
| NBIX | SELL | 2024-07-18 | $135K | — | Filing → |